The Miracle Seat? helps control escape of harmful viruses and bacteria from toilet bowls. "It's the most important advance since the introduction of indoor toilets, 100 years ago. Foul odors and harmful germs are vacuumed out of the toilet bowl before they can get into the air," said Bill Berdux, Senior Vice President of Sales & Marketing at the Miracle Seat Company.
On the heels of information that the state has dropped from first in the nation to 40th in its effort to protect children from the dangers of smoking, the Massachusetts Medical Society and its Alliance have announced the details of the Society's 2004 Anti-Tobacco Poster Contest, a statewide program designed to make young people aware of the dangers of tobacco and smoking.
The Massachusetts Medical Society today applauded the Massachusetts Legislature's passage of Senate 2076, An Act Relative to Electronic Signatures, paving the way for physician use of electronic prescriptions in the Commonwealth.
Former U.S. Senate Majority Leader Bob Dole to Address Vascular Surgeons at VEITHsymposium' International Vascular Surgery Conference
Saying that Pennsylvania's Medicaid program may cost an Altoona man his life by refusing to cover a liver transplant because he has HIV, Lambda Legal will argue its appeal in the case at a hearing tomorrow (Wednesday, Nov. 19), asking the state program to reverse its denial in light of a range of scientific data and the man's personal health history and experience.
Research and Markets have announced the addition of the 'Gastric Cancer Overview - Raising the Standard: Japanese Inspiration and a New Era of Giants' report to their offering.
Provectus Pharmaceuticals (otc bb "pvct") announced today that the Company has an active IND (Investigational New Drug) application for XantrylTM drug therapy with the FDA for Psoriasis.
With an aging population and greater awareness of the problems of bone health of older people, and in particular osteoporosis, comes to the fore, greater emphasis is and will continue to be placed on bone benefit foods. The World Health Organization has defined osteoporosis as the second leading health care problem after cardiovascular disease.
Today, new knowledge in pathology drives a development of more targeted drugs. This 500 page report structures and analyzes the new generation of targeted therapeutics for the treatment of cancer.
The economic impact of cardiovascular disease in the U.S. is enormous. Considered as a whole, the annual cost of treating Americans with CVD currently exceeds US$200 billion. This represents actual expenditures, and is the most spent on any single disease category. But the indirect cost of CVD is just as staggering each year the morbidity and early mortality attributed to CVD represents a drain of over US$140 billion from the U.S. economy in the form of lost productivity. This is a huge burden borne by U.S. employers and reduces American competitiveness around the world.
GPCRs: The Targets of Today's Drugs and Tomorrow's Blockbusters GPCR-directed drug discovery is in its infancy, with product sales of compounds targeting known GPCRs exceeding $30 billion-newly discovered orphan GPCRs have tremendous potential!
The 28 ion channel drugs addressing 5 distinct targets currently generate $12 billion in worldwide sales.
Health and Healing Herb of Fort Lauderdale, FL, has just opened up its online storefront. At www.healthandhealingherb.com there is only one product offer that has become one of the fastest growing herbal tea in the country.
Physicians of the Massachusetts Medical Society (MMS) today adopted several resolutions on significant public health and health policy issues at its 2003 Interim Meeting of its House of Delegates held at the Sheraton Framingham Hotel.
COLA announced today that the Taiwanese Committee for Clinical Laboratory Standards (TCCLS) and Taiwan's Bureau of Pharmaceutical Affairs of Department of Health (BPA/ DOH) have invited COLA to participate in the Training Workshop on Good Biomedical Laboratory Practices (GBLP). This event will take place November 8-9, 2003 in Taipei, Taiwan and address laboratory standards set by accreditation organizations and regulatory agencies.
COLA and the American College of Endocrinology (ACE) have agreed to jointly offer a Laboratory Director Training Program in conjunction with the 2004 Endocrine University - being held at the Mayo Clinic in Rochester, MN, on March 20, 2004. Through this arrangement, COLA and ACE will collectively offer over 20 continuing medical education hours of Category 1 credit. By offering the 20 plus contact hours, this educational program offered by COLA and ACE will meet CLIA requirements for physician-directors of moderate complexity laboratories.
This is a two part report on drug resistant bacteria, as the hidden cause of heart attacks, strokes, cancers, tumors and other gene related diseases. I believe all these diseases are explained in this brief essay, and this information needs to be somehow placed on the Internet, and in front of the rest of the world where it might be read by someone like Bj?rn Nordenstr?m, M.D., Ph.D., (former chairman of the Department of Radiology at Karolinska Hospital and chairman of the selection committee that picks the Nobel Laureate for Physiology of Medicine.)